Rubinstein M C, Fisher R L
Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06510.
Gastroenterologist. 1993 Mar;1(1):71-82.
Medical and surgical management of ulcerative colitis has advanced far in the last decade. New time-released ASA compounds and enemas have decreased the side effects of sulfasalazine and allowed delivery of higher doses of the active compound to the site of action. New steroid compounds have reduced the potential for systemic adrenal glucocorticoid suppression. However, therapy is still directed only against secondary immune and inflammatory responses. Until the cause of UC is discovered, well-designed and well-performed clinical trials must continue to try to identify agents that combine low toxicity with high therapeutic potential.
在过去十年中，溃疡性结肠炎的药物和手术治疗取得了长足进展。新型缓释阿司匹林化合物和灌肠剂减少了柳氮磺胺吡啶的副作用，并能将更高剂量的活性化合物输送到作用部位。新型类固醇化合物降低了全身性肾上腺糖皮质激素抑制的可能性。然而，治疗仍仅针对继发性免疫和炎症反应。在溃疡性结肠炎的病因被发现之前，精心设计和实施的临床试验必须继续进行，以努力找到毒性低且治疗潜力高的药物。
